IMPROVING DIVERSITY STRATEGY
AND IMPLEMENTATION FOR
A TOP 20 PHARMA COMPANY
With pressures from the FDA to improve diversity in clinical studies, a top 20 pharma company turned to COUCH Health to improve their inclusion and diversity strategy to ensure recruited participants are more representative of the population.
Improving diversity and inclusion in clinical studies is something all at COUCH Health are genuinely passionate about. As governing bodies continue to demand better from the industry, we continue to work hard to drive improvement in this area. This enabled us to hit the ground running and devise a plan designed to achieve clear results.
To develop and implement a strategy that would improve the diversity of participants recruited in clinical studies.
Firstly, we identified four key markets:
USA, UK, France and Germany.
In each market, we visited 12 sites to conduct site interviews and pinpointed factors that affect the enrolment of diverse patient populations in clinical research studies.
To keep the research fair, we segmented the 12 research sites in each country into four categories:
86% of the research sites that primarily recruited minority patients implemented cultural competency training to provide an enhanced experience for staff and patients. Only 33.5% of sites recruiting non-minority patients had this training.
During our research, we determined three clear barriers: